Company Interview / Market Update | Cochlear, AMP, Mirvac, Charter Hall Retail REIT, Pro Medicus, GQG

AMP (ASX: AMP) 's profit nearly halved in the 2024 financial year to $150 million - due to the sale of its advice arm and costs associated with simplifying the business.

Cochlear (ASX: COH) has increased its interim dividend by 8% to $2.15 per share. However the hearing implant manufacturer has warned it's expecting annual profit at the lower end of guidance.

Mirvac (ASX: MGR) has eked out a first half statutory profit of one million dollars, reversing a loss of $201 million a year earlier.

Charter Hall Retail REIT (ASX: CQR) has posted a first half profit of nearly $109 million.

GQG Partners (ASX: GQG) has doubled its net flows for the full year, boosting its funds under management to 153 billion US dollars. Unibail-Rodamco-Westfield has hiked its distribution by 40% following strong operating performance and disposal activity in 2024. And Global Lithium has appointed a new CEO and two new board members after losing a months-long boardroom battle with a group of shareholders with alleged Chinese interests at its AGM on Thursday.

Bell Potter has upgraded Pro Medicus (ASX: PME) from hold to 'buy' and has raised its target price to $330. Meanwhile, Citi has lifted its price target of ASX (ASX: ASX) to $68.50 -- observing a downtrend in costs for the stock exchange operator in its last half-year results. And Citi has lowered its price target for Orora to $2.40.